The Persistent Challenge of Relapsed/Refractory Follicular Lymphoma

Follicular lymphoma remains the most common indolent non-Hodgkin lymphoma. Despite high initial response rates to frontline therapy, the disease typically follows a relapsing-remitting course. Specifically, many patients experience progressively shorter durations of remission with each subsequent line of treatment. These clinical patterns emphasize the critical need for more effective salvage strategies. Currently, chemoimmunotherapy serves as a common standard of care for relapsed or refractory follicular lymphoma. However, these regimens are generally not curative and often lead to cumulative toxicities. Therefore, researchers are exploring chemotherapy-free alternatives that can provide deeper and more durable responses. Epcoritamab in follicular lymphoma represents a significant advancement in this therapeutic landscape. As a bispecific antibody, it offers a novel mechanism of action that differs from traditional cytotoxic agents. Consequently, combining this agent with established immunomodulatory drugs could potentially transform patient outcomes. Understanding how these novel combinations compare to usual care is essential for clinicians managing this complex patient population. New data now provide insights into the relative efficacy of these emerging regimens compared to historical standards.

Mechanism of Action: Synergy of the Triplet Regimen

The combination of epcoritamab, lenalidomide, and rituximab (often referred to as E+R2) leverages complementary pathways to enhance antitumor activity. Epcoritamab is a subcutaneously administered CD3 x CD20 bispecific antibody. It functions by simultaneously binding to CD20 on malignant B cells and CD3 on T cells. This dual binding triggers T-cell activation and redirects cytotoxicity specifically toward the cancerous cells. Furthermore, lenalidomide acts as an immunomodulatory agent that enhances the function of T cells and natural killer cells. It also alters the tumor microenvironment to favor immune-mediated destruction of lymphoma cells. Rituximab, the established anti-CD20 monoclonal antibody, contributes through complement-dependent cytotoxicity and antibody-dependent cellular phagocytosis. Interestingly, preclinical studies suggest that epcoritamab and rituximab bind to different epitopes on the CD20 molecule. This lack of competition allows for synergistic activity when used together. Moreover, the addition of epcoritamab appears to augment the efficacy of the R2 backbone without significantly increasing overlapping toxicities. This triplet approach aims to achieve deep molecular remissions that chemoimmunotherapy often fails to provide in later lines of therapy.

Methodology: Comparing Trial Data with Real-World Evidence

To evaluate the clinical benefit of E+R2, investigators conducted an adjusted comparative analysis. They utilized patient-level data from the phase 1b/2 EPCORE NHL-2 trial. This trial enrolled 111 patients with relapsed or refractory follicular lymphoma who had received at least one prior line of therapy. These participants received the triplet combination of epcoritamab plus lenalidomide and rituximab. To provide a meaningful comparison, researchers analyzed real-world data from the COTA electronic health record database. This database included 380 patients from the United States who received usual care, primarily consisting of rituximab-based chemoimmunotherapy. The analysis employed sophisticated statistical techniques, such as inverse probability of treatment weighting, to balance baseline characteristics between the two groups. Specifically, they adjusted for factors like age, disease stage, and the number of previous treatment lines. This methodology allows for a more robust comparison when direct head-to-head randomized trials are not yet available. By aligning the patient profiles, the study could more accurately estimate the therapeutic advantage of the novel bispecific antibody combination over conventional chemotherapy-based approaches.

Key Findings: Superior Efficacy of Epcoritamab in Follicular Lymphoma

The results of the comparative analysis demonstrated a clear advantage for the epcoritamab-containing regimen. Specifically, patients treated with epcoritamab plus R2 achieved a significantly higher overall response rate of 96.9%. In contrast, the group receiving usual chemoimmunotherapy showed an overall response rate of 80.5%. The disparity was even more pronounced when examining complete response rates. In the epcoritamab arm, 88.5% of patients achieved a complete response, compared to only 54.8% in the usual care cohort. These findings suggest that the triplet regimen induces much deeper remissions than standard chemotherapy. Furthermore, the analysis indicated a substantial improvement in progression-free survival for those receiving the novel combination. The hazard ratio for progression or death significantly favored the epcoritamab arm, reflecting a durable benefit. Even in patients who had progressed within 24 months of their first treatment—a high-risk group known as POD24—the triplet regimen maintained its superior efficacy. Consequently, these data support the use of epcoritamab-based therapy as a potent option for difficult-to-treat follicular lymphoma cases. Clinicians can now consider this chemotherapy-free approach with greater confidence in its comparative effectiveness.

Safety Profile and Clinical Management Considerations

While the efficacy of the triplet regimen is impressive, clinicians must remain vigilant regarding its unique safety profile. The most common adverse event associated with epcoritamab is cytokine release syndrome. In the EPCORE NHL-2 trial, most cases of this syndrome were low-grade and occurred primarily during the first cycle of treatment. To mitigate this risk, researchers implemented a step-up dosing schedule and mandatory premedication with corticosteroids. Furthermore, the subcutaneous administration of epcoritamab appears to contribute to a more manageable safety profile compared to some intravenous bispecific antibodies. Other common side effects included neutropenia, fatigue, and injection-site reactions. Most of these events were manageable with standard supportive care or dose adjustments of the partner drugs. For instance, clinicians often adjust lenalidomide doses based on renal function and hematologic recovery. Monitoring for infections is also crucial, especially given the prolonged B-cell depletion associated with anti-CD20 therapies. Overall, the safety data suggest that the E+R2 combination is well-tolerated by most patients. Establishing clear protocols for monitoring and early intervention allows for the safe delivery of this high-efficacy treatment in the outpatient setting.

The Evolving Treatment Landscape for Indian Clinicians

The introduction of epcoritamab in follicular lymphoma therapy marks a pivotal shift toward personalized and targeted immunotherapy. For oncologists in India, these results provide a compelling rationale for adopting bispecific antibodies into clinical practice once available. The ability to avoid traditional chemotherapy while achieving superior response rates is particularly beneficial for elderly or frail patients. Moreover, the fixed-duration nature of the treatment in some protocols offers a significant advantage in terms of treatment burden and cost-effectiveness. As we move forward, the focus will likely shift toward identifying the optimal sequencing of these agents. Questions remain regarding the use of bispecifics before or after CAR-T cell therapy. However, the current data clearly establish the E+R2 triplet as a highly effective bridge or definitive therapy for relapsed disease. Ongoing research continues to explore its use in earlier lines of therapy and in combination with other novel targeted agents. Ultimately, the integration of these advanced immunotherapies promises to improve the quality of life and long-term survival for patients living with follicular lymphoma across the globe.

FAQ

How does epcoritamab differ from traditional rituximab therapy?

Epcoritamab is a bispecific antibody that binds to both CD20 on B cells and CD3 on T cells, directly engaging the immune system to kill cancer cells. Rituximab only binds to CD20 and relies on indirect immune mechanisms like complement activation. Because epcoritamab actively recruits T cells, it often achieves deeper and more rapid responses in patients who have become resistant to traditional monoclonal antibodies or chemotherapy.

What are the primary safety concerns when using epcoritamab with R2?

The most significant concern is cytokine release syndrome, which typically occurs early in the treatment course. Clinicians manage this using step-up dosing and premedication. Other potential issues include neutropenia and an increased risk of infections due to prolonged immune suppression. However, most side effects are low-grade and manageable with standard clinical protocols, making the regimen suitable for many patients who cannot tolerate the toxicity of standard chemoimmunotherapy.

Can this treatment be used for patients who relapsed quickly after first-line therapy?

Yes, the comparative analysis specifically demonstrated that the epcoritamab plus R2 combination is highly effective in high-risk patients, including those with POD24 (progression of disease within 24 months). These patients historically have poor outcomes with standard second-line chemotherapy. The high complete response rates seen with the triplet regimen offer a promising alternative for this difficult-to-treat subgroup, potentially leading to significantly improved long-term survival compared to historical usual care options.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. The use of specific medications should be based on individual patient assessment and the prescribing clinician's judgment. Refer to the latest local and national guidelines for clinical practice.

References

Falchi L et al. Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma. Oncoimmunology. 2026 Dec 31. doi: 10.1080/2162402X.2026.2691549. PMID: 42415230.

Morschhauser F et al. Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a phase 3, randomised, controlled trial. The Lancet. 2026.

Danilov AV et al. Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma. Blood Advances. 2025.